ClinicalTrials.gg
CompletedNCT00290264Updated Jan 24, 2011

SALTO - Symbicort Single Inhaler Therapy Use in Adolescent Adults and Adults With Persistent Asthma

A Phase 3 interventional study of Budesonide/formoterol in Asthma, sponsored by AstraZeneca. Completed at 210 sites in 2 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2011-01-24.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,000
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 110 studies testing budesonide in Asthma — 6 open to participants now, 6 under way, 3 of them phase 3. Budesonide · Asthma.

Enrollment
14th of 108
1,000 · median 124
Started
2004
with 10 others
Phase 3
51 of 110
3 open now
Registered
17th of 110
by date
Lead sponsor
41 of 110
AstraZeneca

Among the 110 studies testing budesonide in Asthma, this one is the 14th largest by enrollment of the 108 interventional ones that give a count, is one of 11 that started in 2004, is one of 51 in phase 3, and was the 17th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

6 of the 110 studies testing budesonide in Asthma are open now, in 5 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About budesonide

Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing budesonide in Asthma, or all of them as a file.
02

Study summary

The primary objective is to compare the efficacy of Symbicort Single inhaler Therapy with treatment according to conventional best practice in adolescent and adult patients with persistent asthma.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Minimum of 3 months documented history of asthma, diagnosed according to the American Thoracic Society (ATS) definition.
  • Prescribed inhaled GCS at a dose of ≥320 µg/day and within the approved label for the relevant drug during the last 3 months prior to Visit 1.

Exclusion criteria

Exclusion Criteria:

  • Use of any b-blocking agent, including eye-drops.
  • Use of oral GCS as maintenance treatment.
  • Known or suspected to study therapy or .
  • A history of smoking ≥ 10 pack years (1 pack year = 1 pack (20 cigarettes) per day for one year or equivalent).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,000 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Time to first severe asthma exacerbation

Secondary outcomes

  1. Number of severe asthma exacerbations

  2. Mean use of as-needed medication

  3. Prescribed asthma medication

  4. Peak Expiratory Flow (PEF)

07

Study locations

210 sites
  • Research Site
    Aalst, Belgium
  • Research Site
    Aartrijke, Belgium
  • Research Site
    Alsemberg, Belgium
  • Research Site
    Anderlecht, Belgium
  • Research Site
    Angleur, Belgium
  • Research Site
    Ans, Belgium
  • Research Site
    Antwerpen, Belgium
  • Research Site
    Anzegem, Belgium
  • Research Site
    Arlon, Belgium
  • Research Site
    Asse, Belgium
  • Research Site
    Aywaille, Belgium
  • Research Site
    Balen, Belgium
  • Research Site
    Barry, Belgium
  • Research Site
    Bastogne, Belgium
  • Research Site
    Battice, Belgium
  • Research Site
    Bellaire, Belgium
  • Research Site
    Berchem, Belgium
  • Research Site
    Bertrix, Belgium
  • Research Site
    Beyne-Heusay, Belgium
  • Research Site
    Bilzen, Belgium
  • Research Site
    Binche, Belgium
  • Research Site
    Bois-de-Villers, Belgium
  • Research Site
    Bornem, Belgium
  • Research Site
    Bouillon, Belgium
  • Research Site
    Boussu, Belgium
  • Research Site
    Brasschaat, Belgium
  • Research Site
    Brugge, Belgium
  • Research Site
    Brussels, Belgium
  • Research Site
    Burdinne, Belgium
  • Research Site
    Casteau, Belgium
  • Research Site
    Champion, Belgium
  • Research Site
    Chapelle-lez-Herlaimont, Belgium
  • Research Site
    Charleroi, Belgium
  • Research Site
    Châtelet, Belgium
  • Research Site
    Chênée, Belgium
  • Research Site
    Corbion, Belgium
  • Research Site
    Couillet, Belgium
  • Research Site
    De Pinte, Belgium
  • Research Site
    Dendermonde, Belgium
  • Research Site
    Deurne, Belgium
  • Research Site
    Diksmuide, Belgium
  • Research Site
    Dinant, Belgium
  • Research Site
    Dour, Belgium
  • Research Site
    Durnal, Belgium
  • Research Site
    Dworp, Belgium
  • Research Site
    Ecaussinnes-d'Enghien, Belgium
  • Research Site
    Ekeren, Belgium
  • Research Site
    Elversele, Belgium
  • Research Site
    Erembodegem, Belgium
  • Research Site
    Erquelinnes, Belgium
  • Research Site
    Escanaffles, Belgium
  • Research Site
    Essen, Belgium
  • Research Site
    Etterbeek, Belgium
  • Research Site
    Evere, Belgium
  • Research Site
    Evergem, Belgium
  • Research Site
    Fleurus, Belgium
  • Research Site
    Frameries, Belgium
  • Research Site
    Ganshoren, Belgium
  • Research Site
    Geluwe, Belgium
  • Research Site
    Genk, Belgium
  • Research Site
    Gent, Belgium
  • Research Site
    Geraardsbergen, Belgium
  • Research Site
    Gilly, Belgium
  • Research Site
    Godinne, Belgium
  • Research Site
    Gozée, Belgium
  • Research Site
    Grand-Halleux, Belgium
  • Research Site
    Graty, Belgium
  • Research Site
    Grivegnée, Belgium
  • Research Site
    Ham-sur-Heure, Belgium
  • Research Site
    Hamme, Belgium
  • Research Site
    Hannut, Belgium
  • Research Site
    Harzé, Belgium
  • Research Site
    Hasselt, Belgium
  • Research Site
    Havinnes, Belgium
  • Research Site
    Havré, Belgium
  • Research Site
    Heist-op-Den-Berg, Belgium
  • Research Site
    Heppen, Belgium
  • Research Site
    Herentals, Belgium
  • Research Site
    Herent, Belgium
  • Research Site
    Herk-de-Stad, Belgium
  • Research Site
    HermalleSousArgenteau, Belgium
  • Research Site
    Herstal, Belgium
  • Research Site
    Hever, Belgium
  • Research Site
    Hoeselt, Belgium
  • Research Site
    Hooglede, Belgium
  • Research Site
    Hornu, Belgium
  • Research Site
    Houthalen-Helchteren, Belgium
  • Research Site
    Huldenberg, Belgium
  • Research Site
    Ieper, Belgium
  • Research Site
    Ingelmunster, Belgium
  • Research Site
    Izegem, Belgium
  • Research Site
    Kalmthout, Belgium
  • Research Site
    Kinrooi-Ophoven, Belgium
  • Research Site
    Kobbegem, Belgium
  • Research Site
    Koksijde, Belgium
  • Research Site
    Kontich, Belgium
  • Research Site
    Koolskamp, Belgium
  • Research Site
    Kortrijk, Belgium
  • Research Site
    Kraainem, Belgium
  • Research Site
    Lauwe, Belgium

Showing the first 100 of 210 sites across 2 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Louis R, Joos G, Michils A, Vandenhoven G. A comparison of budesonide/formoterol maintenance and reliever therapy vs. conventional best practice in asthma management. Int J Clin Pract. 2009 Oct;63(10):1479-88. doi: 10.1111/j.1742-1241.2009.02185.x. PubMed 19769705 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2004 and a completion of Aug 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2006
First posted
Feb 13, 2006
Start
Dec 2004
CompletionActual
Aug 2006
Last update
Jan 24, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00290264
Lead sponsor
AstraZeneca
First posted
Feb 13, 2006
Start date
Dec 2004
Completion
Aug 2006
Last update
Jan 24, 2011

Study contacts

AstraZeneca Belgium Medical Director, MD
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Budesonide · Formoterol

Start the discussion